SCHEMBL2809915

SCHEMBL2809915

CC(C)CCn1ccc(-c2ccc(NC3CCOCC3)cc2)c(Cl)c1=O

nearest known ligand 0.60

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 19/20 0.60
RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810289 0.80 GRM2 (0.51) GRM2RORC
SCHEMBL171300 0.71 GRM2 (0.81) GRM2
SCHEMBL1339018 0.66 GRM2 (0.51) GRM2
SCHEMBL1339020 0.66 GRM2 (0.51) GRM2
SCHEMBL104969 0.65 NPC1 (0.48) RORC
SCHEMBL1338801 0.63 GRM2 (0.43) GRM2
SCHEMBL178453 0.60 MAPK1 (0.53) RORC
SCHEMBL657241 0.60 LMNA (0.45) RORC
SCHEMBL16944207 0.60 GRM2 (1.00) GRM2
SCHEMBL17675010 0.59 PDE1C (0.49) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722894-B2 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-05-13 US disclosed
US-8722894-B2 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-05-13 US disclosed
US-8722894-B2 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones Janssen Pharmaceuticals, Inc. (US) 2014-05-13 US disclosed
EP-2205565-B1 1,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONES JANSSEN PHARMACEUTICALS INC (US) 2013-04-17 EP disclosed
EP-2205565-B1 1,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONES JANSSEN PHARMACEUTICALS INC (US) 2013-04-17 EP disclosed
US-20100240706-A1 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-09-23 US disclosed
US-20100240706-A1 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-09-23 US disclosed
US-20100240706-A1 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2010-09-23 US disclosed
WO-2009033703-A1 1,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONES ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240706-A1 1,3-DISUBSTITUTED-4-PHENYL-1H-PYRIDIN-2-ONES GRM2, GRM1, GRIN2C GRM2 1/4885RORC 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.